OPALINE Study: Observational Study in a Real-World Setting of the Systemic Treatment of Progressive Unresectable or Well-Differentiated Metastatic Pancreatic Neuroendocrine Tumors (pNET)
#2004
Introduction: OPALINE Study focuses on patients with pNET. 2 targeted therapies (TT) offer new options to treat these patients: mTORi (everolimus) and a multi-targeted inhibitor (sunitinib).
Aim(s): Evaluate the impact of both TT versus other treatments (OT) for pNET in a real-world clinical setting.
Materials and methods: We expected 150 patients with well differentiated, progressive, unresectable or metastatic pNET, naïve or pretreated (<5 lines). 2 groups are opened: TT group and OT group (chemotherapy (C), SSA, IFN-α and PRRT).
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author:
Authors: Lombard-Bohas C, Lepage C, Vicaut E, Dominguez S, Coriat R,
Keywords: pNET, targeted therapies,
To read the full abstract, please log into your ENETS Member account.
OPALINE Study: Observational Study in a Real-World Setting of the Systemic Treatment of Progressive Unresectable or Well-Differentiated Metastatic Pancreatic Neuroendocrine Tumors (pNET).
#1842
Introduction: OPALINE Study focuses on patients with pNET. Two targeted therapies (TT) offer new options to treat these patients: mTORi (everolimus) and a multi-targeted inhibitor (sunitinib).
Aim(s): Evaluate the impact of both TT vs other treatments (OT) for pNET in a real-world clinical setting.
Materials and methods: We expected 150 patients with well differentiated, progressive, unresectable or metastatic pNET, naïve or pretreated (<5 lines). 2 cohorts are opened TT group; OT group (chemotherapy,SSA, interferon-alpha and vectorized internal radiation therapy).
Conference: 14th Annual ENETSConcerence (2017)
Presenting Author: Lombard-Bohas V
Authors: Lombard-Bohas C, Lepage C, Vicaut E, Dominguez S, Coriat R,
Keywords: pNET, targeted therapy,
To read the full abstract, please log into your ENETS Member account.